The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Prodromal α-Synucleinopathies Consortium (PαSS) (U19 Clinical Trial Optional)
This funding opportunity announcement (FOA) invites applications to develop a multisite, longitudinal, prospective study of idiopathic REM sleep behavior disorder (iRBD) as a prodromal phase of α-synuclein neurodegenerative disorders.
- Letter of Intent Due Date(s): May 17, 2020
- Application Due Date(s): June 17, 2020
RFA-AG-21-013 Expiration Date June 18, 2020
A multiple-principal investigator (PI) format is required, with one or more PIs with expertise in sleep disorders and one or more PIs with expertise in neurodegenerative diseases, particularly Parkinson’s disease and Lewy Body Dementia
Application budgets are limited to $3 million in direct costs per year.
The maximum project period is 5 years.